Dual-functional bio-derived nanoparticulates for apoptotic antitumor therapy

Biomaterials

Volumn 72, Issue , 2015, Pages 90-103

  Ding, Yang ^a   Wang, Yazhe ^a   Opoku Damoah, Yaw ^a   Wang, Cheng ^a   Shen, Lingjia ^b   Yin, Lifang ^a   Zhou, Jianping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Hengrui Pharmaceuticals Co   (China)

Author keywords

Apoptotic antitumor therapy; Dual functionalization; High density lipoprotein derived nanoparticulates; PH responsive cell penetrating peptide; Synergistic intracellular mechanisms

Indexed keywords

BIOMIMETICS; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; LIPOPROTEINS; PEPTIDES; PHYSICOCHEMICAL PROPERTIES; TUMORS;

ANTI-TUMORS; CELL-PENETRATING PEPTIDE; CELLULAR INTERNALIZATION; FUNCTIONALIZATIONS; HIGH DENSITY LIPOPROTEIN; INHIBITION OF TUMOR GROWTH; NANOPARTICULATES; TRANSMEMBRANE DELIVERIES;

TARGETED DRUG DELIVERY;

APOLIPOPROTEIN A1; CELL PENETRATING PEPTIDE; GAMBOGIC ACID; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; PROTEIN P53; SCAVENGER RECEPTOR BI; ANTINEOPLASTIC AGENT; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; FEMALE; HEPATOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR BINDING; TUMOR GROWTH; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG EFFECTS; ENDOCYTOSIS; INTRACELLULAR SPACE; METABOLISM; NUDE MOUSE; RABBIT; RAT; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DIAGNOSTIC IMAGING; ENDOCYTOSIS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACELLULAR SPACE; LIPOPROTEINS, HDL; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; RABBITS; RATS; XANTHONES;

EID: 84943252155     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.08.051     Document Type: Article

References (53)

1. Peppas N.A. Intelligent therapeutics: biomimetic systems and nanotechnology in drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1529-1531.
2. Spillmann C.M., Naciri J., Algar W.R., Medintz I.L., Delehanty J.B. Multifunctional liquid crystal nanoparticles for intracellular fluorescent imaging and drug delivery. ACS Nano 2014, 8:6986-6997.
3. Xie Y., Qiao H., Su Z., Chen M., Ping Q., Sun M. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy. Biomaterials 2014, 35:7978-7991.
4. Yoo J.-W., Irvine D.J., Discher D.E., Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 2011, 10:521-535.
5. Yang M., Jin H., Chen J., Ding L., Ng K.K., Lin Q., et al. Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 2011, 7:568-573.
6. Shahzad M.M., Mangala L.S., Han H.D., Lu C., Bottsford-Miller J., Nishimura M., et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011, 13. 309-IN8.
7. MacEwan S.R., Callahan D.J., Chilkoti A. Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine 2010, 5:793-806.
8. Moitra P., Kumar K., Kondaiah P., Bhattacharya S. Efficacious anticancer drug delivery mediated by a pH-sensitive self-assembly of a conserved tripeptide derived from tyrosine kinase NGF receptor. Angew. Chem. Int. Ed. 2014, 53:1113-1117.
9. Takemoto H., Miyata K., Hattori S., Ishii T., Suma T., Uchida S., et al. Acidic pH-responsive siRNA conjugate for reversible carrier stability and accelerated endosomal escape with reduced IFNα-associated immune response. Angew. Chem. 2013, 125:6338-6341.
10. Kang J.-H., Toita R., Kim C.W., Katayama Y. Protein kinase C (PKC) isozyme-specific substrates and their design. Biotechnol. Adv. 2012, 30:1662-1672.
11. Lee B.-S., Amano T., Wang H.Q., Pantoja J.L., Yoon C.W., Hanson C.J., et al. Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma. ACS Nano 2013, 7:3061-3077.
12. Zorko M., Langel Ü. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 2005, 57:529-545.
13. Wang F., Wang Y., Zhang X., Zhang W., Guo S., Jin F. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J. Control. Release 2014, 174:126-136.
14. Zhang Q., Tang J., Fu L., Ran R., Liu Y., Yuan M., et al. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 2013, 34:7980-7993.
15. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
16. Mathew S., Murakami T., Nakatsuji H., Okamoto H., Morone N., Heuser J.E., et al. Exclusive photothermal heat generation by a gadolinium bis(naphthalocyanine) complex and inclusion into modified high-density lipoprotein nanocarriers for therapeutic applications. ACS Nano 2013, 7:8908-8916.
17. He H., Ye J., Wang Y., Liu Q., Chung H.S., Kwon Y.M., et al. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J. Control. Release 2014, 176:123-132.
18. Ng K.K., Lovell J.F., Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 2011, 44:1105-1113.
19. Murakami T., Nakatsuji H., Morone N., Heuser J.E., Ishidate F., Hashida M., et al. Mesoscopic metal nanoparticles doubly functionalized with natural and engineered lipidic dispersants for therapeutics. ACS Nano 2014, 8:7370-7376.
20. Pandey M.K., Sung B., Ahn K.S., Kunnumakkara A.B., Chaturvedi M.M., Aggarwal B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway. Blood 2007, 110:3517-3525.
21. Duan D., Zhang B., Yao J., Liu Y., Sun J., Ge C., et al. Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase. Free Radic. Biol. Med. 2014, 69:15-25.
22. Qin Y., Meng L., Hu C., Duan W., Zuo Z., Lin L., et al. Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain. Mol. Cancer Ther. 2007, 6:2429-2440.
23. Kasibhatla S., Jessen K.A., Maliartchouk S., Wang J.Y., English N.M., Drewe J., et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12095-12100.
24. Gu H., Wang X., Rao S., Wang J., Zhao J., Ren F.L., et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol. Cancer Ther. 2008, 7:3298-3305.
25. Zhai D., Jin C., Shiau C.-W., Kitada S., Satterthwait A.C., Reed J.C. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol. Cancer Ther. 2008, 7:1639-1646.
26. Lerch P.G., Förtsch V., Hodler G., Bolli R. Production and Characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 1996, 71:155-164.
27. Zhang W., He H., Liu J., Wang J., Zhang S., Zhang S., et al. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials 2013, 34:306-319.
28. Zhang W.-L., Xiao Y., Liu J.-P., Wu Z.-M., Gu X., Xu Y.-M., et al. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int. J. Pharm. 2011, 419:314-321.
29. He H., Liu L., Bai H., Wang J., Zhang Y., Zhang W., et al. Arachidonic acid-modified lovastatin discoidal reconstituted high density lipoprotein markedly decreases the drug leakage during the remodeling behaviors induced by lecithin cholesterol acyltransferase. Pharm. Res. 2014, 1-21.
30. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
31. El-Sayed A., Futaki S., Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 2009, 11:13-22.
32. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422:37-44.
33. Mo R., Sun Q., Xue J., Li N., Li W., Zhang C., et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery. Adv. Mater. 2012, 24:3659-3665.
34. Mo R., Jiang T., Gu Z. Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery. Angew. Chem. 2014, 126:5925-5930.
35. Shigeta K., Kawakami S., Higuchi Y., Okuda T., Yagi H., Yamashita F., et al. Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. J. Control. Release 2007, 118:262-270.
36. Wang C., Bao X., Ding X., Ding Y., Abbad S., Wang Y., et al. A multifunctional self-dissociative polyethyleneimine derivative coating polymer for enhancing the gene transfection efficiency of DNA/polyethyleneimine polyplexes in vitro and in vivo. Polym. Chem. 2015, 6:780-796.
37. Schmid S.L., Carter L.L. ATP is required for receptor-mediated endocytosis in intact cells. J. Cell Biol. 1990, 111:2307-2318.
38. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2006, 2:47-52.
39. Silverstein S.C., Steinman R.M., Cohn Z.A. Endocytosis. Annu. Rev. Biochem. 1977, 46:669-722.
40. Daukas G., Zigmond S.H. Inhibition of receptor-mediated but not fluid-phase endocytosis in polymorphonuclear leukocytes. J. Cell Biol. 1985, 101:1673-1679.
41. Larkin J.M., Brown M.S., Goldstein J.L., Anderson R.G. Depletion of intracellular potassium arrests coated pit formation and receptor-mediated endocytosis in fibroblasts. Cell 1983, 33:273-285.
42. Koren E., Torchilin V.P. Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 2012, 18:385-393.
43. Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 2004, 10:310-315.
44. Ding Y., Wang Y., Zhou J., Gu X., Wang W., Liu C., et al. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials 2014, 35:7214-7227.
45. Murakami T., Wijagkanalan W., Hashida M., Tsuchida K. Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine 2010, 5:867-879.
46. Zhang H.-Z., Kasibhatla S., Wang Y., Herich J., Guastella J., Tseng B., et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg. Med. Chem. 2004, 12:309-317.
47. Li C., Lu N., Qi Q., Li F., Ling Y., Chen Y., et al. Gambogic acid inhibits tumor cell adhesion by suppressing integrin β1 and membrane lipid rafts-associated integrin signaling pathway. Biochem. Pharmacol. 2011, 82:1873-1883.
48. Zhang L., Yi Y., Chen J., Sun Y., Guo Q., Zheng Z., et al. Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells. Biochem. Biophys. Res. Commun. 2010, 403:282-287.
49. Davenport J., Manjarrez J.R., Peterson L., Krumm B., Blagg B.S., Matts R.L. Gambogic acid, a natural product inhibitor of Hsp90. J. Nat. Prod. 2011, 74:1085-1092.
50. Prasad S., Pandey M.K., Yadav V.R., Aggarwal B.B. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev. Res. 2011, 4:1084-1094.
51. Yang L.-J., Chen Y. New targets for the antitumor activity of gambogic acid in hematologic malignancies. Acta Pharmacol. Sin. 2012, 34:191-198.
52. Tiera M.J., Shi Q., Winnik F.M., Fernandes J.C. Polycation-based gene therapy: current knowledge and new perspectives. Curr. Gene Ther. 2011, 11:288-306.
53. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 2010, 18:53-58.